Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.04 USD | -0.05% | -1.70% | +8.55% |
May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.55% | 1.35B | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.46% | 21.83B | |
-11.04% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $32 From $35 on Estimated Mavrilimumab Launch Date; Outperform Rating Kept